Abiopharma

🔍 Van Hoose Kyri K. (Executive)

Company: Dermata Therapeutics, Inc. (DRMA)

Report Date: 2026-08-16

Detailed Transactions and Holdings:

• Acquired 102,040 shares of Common Stock (Direct)
  Date: 2026-08-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 232,463.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Acquired 102,040 shares of Series E Warrant (Right to Buy) at $1.47 per share (Derivative)
  Date: 2026-08-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 102,040.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3, F3
• Acquired 102,040 shares of Series F Warrant (Right to Buy) at $1.47 per share (Derivative)
  Date: 2026-08-16 | Code: A | equity_swap_involved: 0 | shares_owned_after: 102,040.00 | transaction_form_type: 4 | Footnotes: F1, F2, F4, F4

Footnotes:

• F1: The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock.
• F2: The purchase price per share of common stock and accompanying warrants was $1.47.
• F3: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.
• F4: This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire two years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.